Symptom Targeted Intervention (or STI) is a proprietary program created in 2010 to help patients improve clinical outcomes and engage more in their healthcare. Since then, STI has been rolled out to over 5000 clinics and hospitals across the US, UK, and Canada. Research suggests that it decrease depression, missed treatments, hospitalizations and anxiety and increases quality of life score and patient engagement .
STI is being used by Kaiser Permanente, DaVita, FMC, among others and saves an average of $2-14K per patient per year due to improved treatment adherence and decreased hospitalization rates. We are 85% penetrated in US renal clinics, and are scaling our program to other clinical contexts such as chronic care management and hospital readmission prevention.
We have active pilot programs with 3 university hospitals and 2 private hospital chains to test new clinical applications of STI. Our revenue is derived from a combination of licensing fees, implementation consulting, and physical products.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2011
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was STI Innovations founded?
STI Innovations was founded in 2011.
What industry is STI Innovations in?
STI Innovations operates in Hospital & Health Care. Find similar Hospital & Health Care investors on gritt.io.
Where is STI Innovations based?
STI Innovations is headquartered in Encinitas, United States.
Find investors for your startup like STI Innovations
Gritt sends AI-personalised outreach to each investor — from your Gmail